(Q46983142)

27 December 2017

title

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer (English)

1 reference

27 December 2017

1 reference

1 reference

1 reference

1

1 reference

27 December 2017

author name string

Sue Valmadre

2

1 reference

27 December 2017

Kimberly E Resnick

3

1 reference

27 December 2017

Lynne A Eaton

4

1 reference

27 December 2017

Larry J Copeland

5

1 reference

27 December 2017

Jeffrey M Fowler

6

1 reference

27 December 2017

language of work or name

English

0 references

publication date

9 March 2006

1 reference

27 December 2017

published in

Gynecologic Oncology

1 reference

27 December 2017

volume

102

1 reference

27 December 2017

issue

2

1 reference

27 December 2017

page(s)

134-139

1 reference

27 December 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Vascular endothelial growth factor is a secreted angiogenic mitogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Clinical translation of angiogenesis inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.01.030

10.1016/J.YGYNO.2006.01.030

7 January 2021

Identifiers

DOI

1 reference

27 December 2017

PubMed ID

16527339

1 reference

27 December 2017